Synthesis of cycloruthenated compounds as potential anticancer agents

被引：77
作者：
Leyva, Lida
Sirlin, Claude
Rubio, Laura
Franco, Cecilia
Le Lagadec, Ronan
Spencer, John
Bischoff, Pierre
Gaiddon, Christian
Loeffler, Jean-Philippe
Pfeffer, Michel
机构：
[1] Univ Strasbourg, CNRS, Inst Chim Strasbourg, F-67000 Strasbourg, France
[2] Univ Nacl Autonoma Mexico, Inst Quim, Mexico City 04510, DF, Mexico
[3] Univ Greenwich, Sch Sci, Chatham ME4 4TB, Kent, England
[4] Hop Univ, IRCAD, UPREA EA 3430, Lab Alterat Genet Canc & Reponse Therapeut, Strasbourg, France
[5] Univ Strasbourg, INSERM, U 692, Lab Signalizat Mol & Neurodegenerescence, F-67000 Strasbourg, France
来源：
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY | 2007年 / 19期
关键词：
bioinorganic chemistry; ruthenium; metallacycles; antitumor agents;
D O I：
10.1002/ejic.200601149
中图分类号：
O61 [无机化学];
学科分类号：
070301 ; 081704 ;
摘要：
A library of 19 cycloruthenated derivatives is constructed by making use of the well-known cyclometalation reaction. Their geometries are modified in a straightforward manner by addition of either mono- or bidentate ligands, such as bipyridine, phenanthroline, 1,2-bis(diphenylphosphanyl)ethane, dimethylphenylphosphane, triphenylphosphane, and 1,3,5-triaza-7-phosphatricyclo[3.3.1.1]decane (PTA) ligands, to cationic cycloruthenated centers. The antitumor properties of the compounds thus obtained are investigated in order to compare them with recently reported ruthenium complexes and cisplatin. IC50 values against mammalian cells (A-172, HCT-116, and RDM-4) are determined for the library compounds and some of them, such as those derived from orthoruthenated phenylpyridine and a bidentate N,N ligand, display activity of the same order of magnitude as cisplatin. ((c) Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinhem, Germany, 2007).
引用
收藏
页码：3055 / 3066
页数：12
相关论文
共 53 条
[1]   CARBON-CARBON AND CARBON-NITROGEN BOND FORMATION MEDIATED BY RUTHENIUM(II) COMPLEXES - SYNTHESIS OF (1H)-ISOQUINOLINIUM DERIVATIVES [J].
ABBENHUIS, HCL ;
PFEFFER, M ;
SUTTER, JP ;
DECIAN, A ;
FISCHER, J ;
JI, HL ;
NELSON, JH .
ORGANOMETALLICS, 1993, 12 (11) :4464-4472
[2]  
AIGLE DJ, 1998, INORG SYNTH, V32, P40
[3]   In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer [J].
Aird, RE ;
Cummings, J ;
Ritchie, AA ;
Muir, M ;
Morris, RE ;
Chen, H ;
Sadler, PJ ;
Jodrell, DI .
BRITISH JOURNAL OF CANCER, 2002, 86 (10) :1652-1657
[4]  
Allardyce CS, 2001, PLATIN MET REV, V45, P62
[5]   Synthesis and characterisation of some water soluble ruthenium(II)-arene complexes and an investigation of their antibiotic and antiviral properties [J].
Allardyce, CS ;
Dyson, PJ ;
Ellis, DJ ;
Salter, PA ;
Scopelliti, R .
JOURNAL OF ORGANOMETALLIC CHEMISTRY, 2003, 668 (1-2) :35-42
[6]   Classical and non-classical ruthenium-based anticancer drugs: Towards targeted chemotherapy [J].
Ang, Wee Han ;
Dyson, Paul J. .
EUROPEAN JOURNAL OF INORGANIC CHEMISTRY, 2006, (20) :4003-4018
[7]   METALLACYCLES WITH STEREOGENIC METAL CENTERS - SYNTHESIS AND CHARACTERIZATION OF DIASTEREOMERIC CYCLORUTHENATED CHIRAL AMINES [J].
ATTAR, S ;
NELSON, JH ;
FISCHER, J ;
DECIAN, A ;
SUTTER, JP ;
PFEFFER, M .
ORGANOMETALLICS, 1995, 14 (10) :4559-4569
[8]   Chiral cyclopalladated complexes derived from N,N-dimethyl-1-phenethylamine with bridging bis(diphenylphosphine)ferrocene ligand as inhibitors of the cathepsin B activity and as antitumoral agents [J].
Bincoletto, C ;
Tersariol, ILS ;
Oliveira, CR ;
Dreher, S ;
Fausto, DM ;
Soufen, MA ;
Nascimento, FD ;
Caires, ACF .
BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (08) :3047-3055
[9]   THERMAL AND LIGHT-INDUCED DECOMPOSITION OF AZIDO(BIS-2,2'-BIPYRIDINE) COMPLEXES OF RUTHENIUM(III) [J].
BROWN, GM ;
CALLAHAN, RW ;
MEYER, TJ .
INORGANIC CHEMISTRY, 1975, 14 (08) :1915-1921
[10]   Non-platinum chemotherapeutic metallopharmaceuticals [J].
Clarke, MJ ;
Zhu, FC ;
Frasca, DR .
CHEMICAL REVIEWS, 1999, 99 (09) :2511-2533
123456